634 related articles for article (PubMed ID: 25043204)
21. Huperzine A inhibits CCL2 production in experimental autoimmune encephalomyelitis mice and in cultured astrocyte.
Tian GX; Zhu XQ; Chen Y; Wu GC; Wang J
Int J Immunopathol Pharmacol; 2013; 26(3):757-64. PubMed ID: 24067473
[TBL] [Abstract][Full Text] [Related]
22. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
[TBL] [Abstract][Full Text] [Related]
23. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
24. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
25. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
26. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
28. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
29. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Lewis ND; Haxhinasto SA; Anderson SM; Stefanopoulos DE; Fogal SE; Adusumalli P; Desai SN; Patnaude LA; Lukas SM; Ryan KR; Slavin AJ; Brown ML; Modis LK
J Immunol; 2013 Apr; 190(7):3533-40. PubMed ID: 23436932
[TBL] [Abstract][Full Text] [Related]
30. The impact of regional astrocyte interferon-γ signaling during chronic autoimmunity: a novel role for the immunoproteasome.
Smith BC; Sinyuk M; Jenkins JE; Psenicka MW; Williams JL
J Neuroinflammation; 2020 Jun; 17(1):184. PubMed ID: 32532298
[TBL] [Abstract][Full Text] [Related]
31. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.
Bassi R; Anelli V; Giussani P; Tettamanti G; Viani P; Riboni L
Glia; 2006 Apr; 53(6):621-30. PubMed ID: 16470810
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760
[TBL] [Abstract][Full Text] [Related]
33. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
Airas L; Dickens AM; Elo P; Marjamäki P; Johansson J; Eskola O; Jones PA; Trigg W; Solin O; Haaparanta-Solin M; Anthony DC; Rinne J
J Nucl Med; 2015 Feb; 56(2):305-10. PubMed ID: 25572093
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
35. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
36. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Balatoni B; Storch MK; Swoboda EM; Schönborn V; Koziel A; Lambrou GN; Hiestand PC; Weissert R; Foster CA
Brain Res Bull; 2007 Oct; 74(5):307-16. PubMed ID: 17845905
[TBL] [Abstract][Full Text] [Related]
37. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
[TBL] [Abstract][Full Text] [Related]
38. FTY720 requires vitamin B
Jonnalagadda D; Kihara Y; Groves A; Ray M; Saha A; Ellington C; Lee-Okada HC; Furihata T; Yokomizo T; Quadros EV; Rivera R; Chun J
Cell Rep; 2023 Dec; 42(12):113545. PubMed ID: 38064339
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound.
Cavone L; Felici R; Lapucci A; Buonvicino D; Pratesi S; Muzzi M; Hakiki B; Maggi L; Peruzzi B; Caporale R; Annunziato F; Amato MP; Chiarugi A
Brain Behav Immun; 2015 Nov; 50():78-86. PubMed ID: 26130058
[TBL] [Abstract][Full Text] [Related]
40. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Miron VE; Ludwin SK; Darlington PJ; Jarjour AA; Soliven B; Kennedy TE; Antel JP
Am J Pathol; 2010 Jun; 176(6):2682-94. PubMed ID: 20413685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
